Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis
Abstract
PURPOSE OF REVIEW: This article synthesizes current preclinical and clinical literature regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in rheumatoid arthritis (RA), highlights mechanistic hypotheses and explores potential clinical roles and limitations of their use. RECENT FINDINGS: GLP-1 RAs are established therapies for type 2 diabetes mellitus and obesity, with demonstrated benefits on glycemic control and cardiovascular risk reduction. Emerging evidence suggests that GLP-1 RAs may exert anti-inflammatory and immunomodulatory effects relevant to RA. SUMMARY: Present evidence is insufficient to recommend GLP-1 RAs as standard RA therapy. Well designed randomized controlled trials are needed to establish their efficacy and optimal role.
Fields of Study & Subjects
Diabetes Treatment and Management
Rheumatoid Arthritis Research and Therapies
Heart Failure Treatment and Management
Publication details
- Journal / source
- Current Opinion in Rheumatology
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Volume
- 38
- Issue
- 4
- Pages
- 250–254
- Publication date
- 5 March 2026
- Language
- EN